OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder

@inproceedings{Sievert2014OnabotulinumtoxinA1P,
  title={OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder},
  author={Karl-Dietrich Sievert and Christopher Key Chapple and Sender Herschorn and Manjari Joshi and J Zhou and Christopher Nardo and Victor W. Nitti},
  booktitle={International journal of clinical practice},
  year={2014}
}
INTRODUCTION A prespecified pooled analysis of two placebo-controlled, phase 3 trials evaluated whether the number of prior anticholinergics used or reason for their discontinuation affected the treatment response to onabotulinumtoxinA 100U in overactive bladder (OAB) patients with urinary incontinence (UI). METHODS Patients with symptoms of OAB received intradetrusor injections of onabotulinumtoxinA 100U or placebo, sparing the trigone. Change from baseline at week 12 in UI episodes/day… CONTINUE READING
18 Citations
26 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Piv - otal phase 3 study in overactive bladder ( OAB ) patients with urinary incontinence confirms onabotulinumtoxinA 100 U significantly improves all OAB symptoms and patients ’ quality of life

  • MJ Smith, LA Miller, J Doyle, R Ariely
  • Eur Urol Suppl
  • 2013

Similar Papers

Loading similar papers…